Ethical Implications of Continuing Oral Immunotherapy After the Development of Eosinophilic Esophagitis
The Journal of Allergy and Clinical Immunology: In Practice · 2023
DOI: 10.1016/j.jaip.2023.08.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023. Verfasst von Bridget E Wilson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Asthma, and Clinical Immunology, Department of Medicine, Mayo Clinic, Scottsdale, Ariz; Section of Allergy and Immunology, Divis…. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Enteritis, Gastritis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory disease requiring maintenance therapy. Traditionally, EoE has been a contraindication to oral immunotherapy (OIT) and a rationale for discontinuing treatment because OIT may induce EoE. Most, but not all patients with OIT-induced EoE experience symptom resolution and histologic remission after discontinuing OIT. Recent studies report OIT continuation even after EoE onset, despite the previously accepted standard of care. This creates clinical as well as ethical challenges for allergists treating these patients. Considering the published literature on EoE and OIT and the primary medical ethics principles of beneficence, nonmaleficence, autonomy, and justice, we discuss the ethical implications of pursuing desensitization despite the potential complications associated with EoE. When ethical principles are in opposition, shared decision-making should be employed to determine whether OIT should be continued after an EoE diagnosis. This article highlights the ethical dilemmas allergists face when determining whether patients with a diagnosis of EoE should continue OIT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Allergy, Asthma, and Clinical Immunology, Department of Medicine, Mayo Clinic, Scottsdale, Ariz; Section of Allergy and Immunology, Division of Pulmonology, Phoenix Children's Hospital, Phoenix, Ariz. Electr…
- Division of General Internal Medicine and Office of Experience, Mayo Clinic, Scottsdale, Ariz.
- Division of Allergy, Asthma, and Clinical Immunology, Department of Medicine, Mayo Clinic, Scottsdale, Ariz; Section of Allergy and Immunology, Division of Pulmonology, Phoenix Children's Hospital, Phoenix, Ariz.
Förderung
- NIAID NIH HHS
- National Institutes of Health
Zitieren
APA
Wilson, B. E., Meltzer, E. C., & Wright, B. L. (2023). Ethical Implications of Continuing Oral Immunotherapy After the Development of Eosinophilic Esophagitis. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2023.08.012
Vancouver
Wilson BE, Meltzer EC, Wright BL. Ethical Implications of Continuing Oral Immunotherapy After the Development of Eosinophilic Esophagitis. The Journal of Allergy and Clinical Immunology: In Practice. 2023. doi:10.1016/j.jaip.2023.08.012
BibTeX
@article{Wilson2023,
author = {Wilson, Bridget E and Meltzer, Ellen C and Wright, Benjamin L},
title = {Ethical Implications of Continuing Oral Immunotherapy After the Development of Eosinophilic Esophagitis},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2023},
doi = {10.1016/j.jaip.2023.08.012}
}
EUVIMED